Biogen Inc. is a biopharmaceutical firm dedicated to the discovery, advancement, and provision of treatments for conditions affecting the nervous system. Headquartered in Cambridge, Massachusetts, the company employs 7,800 full-time staff. Its primary focus involves the research, development, production, and distribution of therapies targeting a range of severe neurological, rare, and autoimmune disorders. Among its commercialized pharmaceutical offerings are medications such as TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA, all prescribed for multiple sclerosis (MS). Additionally, Biogen provides FUMADERM for severe plaque psoriasis and SPINRAZA for individuals with spinal muscular atrophy (SMA). Biogen also maintains a strategic alliance with Genentech, Inc., a member of the Roche Group. This partnership covers products like RITUXAN, utilized for conditions such as non-Hodgkin's lymphoma and chronic lymphocytic leukemia (CLL), and GAZYVA, indicated for CLL and follicular lymphoma, alongside other anti-CD20-based treatments. The company's development pipeline features numerous experimental therapies, including OCREVUS, Biosimilar adalimumab, Aducanumab, E2609, BIIB074, BAN2401, Opicinumab, CIRARA, BIIB061, BIIB054, BIIB067, and BIIB068.
